Todos wins Notice of Allowance from European Patent Office for patent covering cancer diagnosis using TBIA Immune Profiling

Todos Medical Ltd (OTCQB:TOMDF), a medical diagnostics solutions company, revealed that it has received a notice of allowance from the European Patent Office covering the use of the company’s proprietary Total Biochemical Infrared Analysis (TBIA) platform to diagnose cancers.

The TBIA method uses blood – plasma and/or peripheral blood mononuclear cells (PBMCs) – to distinguish between patients with benign tumors versus malignant tumors in contrast to no tumors (healthy controls).

The Todos patent application specifically covers methods for capturing consistent data from infrared spectroscopy readers, as well as the application of various artificial intelligence algorithm development methods to the data.

READ: Todos strikes distribution partnership with OHC for GeneFinder COVID-19 Plus RealAMP Kit in US

“The ability of TBIA to make a diagnosis of cancer has first been applied to the detection of breast and colon cancers, where Todos has received CE Marks in Europe paving the way for commercialization initially focused on TMB-2 (dense breast /inconclusive mammogram secondary screening) and TMB-1 (general breast cancer screening) cancer detection tests),” the company noted.

“As we continue to expand our patent position in the blood-based spectroscopy cancer detection market, we are extremely pleased with the progress being made by our development partners in Singapore and Israel who have been steadily advancing our TBIA platform for commercialization outside the US,” said Todos CEO Gerald E Commissiong in a statement.

“TBIA represents a potentially game-changing approach to cancer detection because we will be able to run different artificial intelligence-developed algorithms for multiple cancer types on the same blood sample,” he added.

Commissiong noted that while the focus is initially on “improving the diagnosis of breast cancer and colon cancer” using this method, the potential applies to all cancers.

“Our vision is to develop a single, simple and cost-effective blood test that can identify any cancer at its earliest stages of formation, and then use emerging methods such as liquid biopsy to monitor patient responses to treatment,” added Commissiong. “Because TBIA is so simple and cost-effective to use, we believe that this technology will compete extremely well with liquid biopsy for the cancer screening market.”

Founded in Rehovot, Israel with offices in New York City, Todos is positioning TBIA to become a routine screening test done for cancer in a variety of patient screening settings worldwide.

In August 2020, Todos struck a strategic partnership with Singapore-based Pathnova Laboratories, a spinout of Temasek Life Sciences Laboratory, to optimize TBIA’s artificial intelligence cancer detection engine and commercialize TBIA in Singapore.

Then in September last year, Todos expanded its partnership with Israel-based Care GB by forming a joint venture called BioImagery Ltd to support the commercialization of the cancer portion of Todos’ TBIA immune profiling platform in Israel, Europe and Africa.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Story by ProactiveInvestors